Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT-1: BGM0504 vs semaglutide in early type 2 diabetes with obesity
CTR20255207Phase 3Active
- Sponsor
- Borray New Creation Biopharmaceutical Technology
- Start
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of BGM0504 in type 2 diabetes mellitus (T2DM), obesity, sponsored by Borray New Creation Biopharmaceutical Technology. Started Dec 2025; status: active.
02
Drugs
BGM0504
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on CTR20255207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255207.